Signal transduction in the human thyrocyte and its perversion in thyroid tumors

Molecular and Cellular Endocrinology

Volumn 321, Issue 1, 2010, Pages 3-19

  Roger, Pierre P ^a   van Staveren, Wilma C G ^a   Coulonval, Katia ^a   Dumont, Jacques E ^a   Maenhaut, Carine ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Caveats; Growth factor pathway; Models; Signal transduction; Thyroid carcinomas; TSH pathways

Indexed keywords

BETA CATENIN; CYCLIC AMP; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR PAX8;

CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HYPERTHYROIDISM; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THYROID ADENOMA; THYROID CANCER; THYROID CELL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

ANIMALS; GENES, NEOPLASM; HUMANS; SIGNAL TRANSDUCTION; THYROID GLAND; THYROID NEOPLASMS;

EID: 77950961448     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.11.015     Document Type: Review

References (199)

1. Aasland R., Akslen L.A., Varhaug J.E., Lillehaug J.R. Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid. Int. J. Cancer 1990, 46:382-387.
2. Alberti L., Carniti C., Miranda C., Roccato E., Pierotti M.A. RET and NTRK1 proto-oncogenes in human diseases. J. Cell Physiol 2003, 195:168-186.
3. Avvedimento V.E., Musti A.M., Ueffing M., Obici S., Gallo A., Sanchez M., DeBrasi D., Gottesman M.E. Reversible inhibition of a thyroid-specific trans-acting factor by Ras. Genes Dev. 1991, 5:22-28.
4. Banu S.K., Arosh J.A., Govindarajulu P., Aruldhas M.M. Testosterone and estradiol differentially regulate thyroid growth in Wistar rats from immature to adult age. Endocr. Res. 2001, 27:447-463.
5. Baptist M., Dumont J.E., Roger P.P. Intercellular heterogeneity of early mitogenic events: cAMP generalizes the EGF effect on c-Fos protein appearance but not on MAP kinase phosphorylation and nuclear translocation in dog thyroid epithelial cells. Exp. Cell Res. 1995, 221:160-171.
6. Baptist M., Lamy F., Gannon J., Hunt T., Dumont J.E., Roger P.P. Expression and subcellular localization of CDK2 and cdc2 kinases and their common partner cyclin A in thyroid epithelial cells: comparison of cyclic AMP-dependent and -independent cell cycles. J. Cell Physiol. 1996, 166:256-273.
7. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 1996, 8:805-814.
8. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 1998, 17:1027-1037.
9. Battaglia C., Berlingieri M.T., Martelli M.L., Trapasso F., Delli B.P., Fusco A. Mitogenic and dedifferentiating effect of the K-fgf/hst oncogene on rat thyroid PC clone 3 epithelial cells. Cell Growth Differ. 1993, 4:185-192.
10. Belfiore A., Pandini G., Vella V., Squatrito S., Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 1999, 81:403-407.
11. Bockstaele L., Bisteau X., Paternot S., Roger P.P. Differential regulation of CDK4 and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Mol. Cell. Biol. 2009, 29.
12. Bockstaele L., Coulonval K., Kooken H., Paternot S., Roger P.P. Regulation of CDK4. Cell Division 2006, 1:25.
13. Bockstaele L., Kooken H., Libert F., Paternot S., Dumont J.E., de Launoit Y., Roger P.P., Coulonval K. Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK " inhibitors" Mol. Cell Biol. 2006, 26:5070-5085.
14. Bongarzone I., Fugazzola L., Vigneri P., Mariani L., Mondellini P., Pacini F., Basolo F., Pinchera A., Pilotti S., Pierotti M.A. Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1996, 81:2006-2009.
15. Bounacer A., McGregor A., Skinner J., Bond J., Poghosyan Z., Wynford-Thomas D. Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways. Oncogene 2004, 23:7839-7845.
16. Brewer C., Yeager N., Di Cristofano A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res. 2007, 67:8002-8006.
17. Burikhanov R., Coulonval K., Pirson I., Lamy F., Dumont J.E., Roger P.P. Thyrotropin via cyclic AMP induces insulin receptor expression and insulin co-stimulation of growth and amplifies insulin and insulin-like growth factor signaling pathways in dog thyroid epithelial cells. J. Biol. Chem. 1996, 271:29400-29406.
18. Burniat A., Jin L., Detours V., Driessens N., Goffard J.C., Santoro M., Rothstein J., Dumont J.E., Miot F., Corvilain B. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. Endocrinology 2008, 149:5107-5117.
19. Carta C., Moretti S., Passeri L., Barbi F., Avenia N., Cavaliere A., Monacelli M., Macchiarulo A., Santeusanio F., Tartaglia M., Puxeddu E. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin. Endocrinol. (Oxford) 2006, 64:105-109.
20. Cass L.A., Meinkoth J.L. Differential effects of cyclic adenosine 3′,5′-monophosphate on p70 ribosomal S6 kinase. Endocrinology 1998, 139:1991-1998.
21. Cass L.A., Meinkoth J.L. Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation. Oncogene 2000, 19:924-932.
22. Cass L.A., Summers S.A., Prendergast G.V., Backer J.M., Birnbaum M.J., Meinkoth J.L. Protein kinase A-dependent and -independent signaling pathways contribute to cyclic AMP-stimulated proliferation. Mol. Cell Biol. 1999, 19:5882-5891.
23. Castellone M.D., De F.V., Rao D.M., Bellelli R., Muthu M., Basolo F., Fusco A., Gutkind J.S., Santoro M. The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res. 2009, 69:1867-1876.
24. Castro P., Rebocho A.P., Soares R.J., Magalhaes J., Roque L., Trovisco V., Vieira d.C.I., Cardoso-de-Oliveira M., Fonseca E., Soares P., Sobrinho-Simoes M. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2006, 91:213-220.
25. Ciampi R., Giordano T.J., Wikenheiser-Brokamp K., Koenig R.J., Nikiforov Y.E. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr. Relat. Cancer 2007, 14:445-452.
26. Ciampi R., Knauf J.A., Kerler R., Gandhi M., Zhu Z., Nikiforova M.N., Rabes H.M., Fagin J.A., Nikiforov Y.E. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 2005, 115:94-101.
27. Ciampi R., Nikiforov Y.E. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007, 148:936-941.
28. Clement S., Refetoff S., Robaye B., Dumont J.E., Schurmans S. Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-Ir receptor in the thyroid gland. Endocrinology 2001, 142:5131-5139.
29. Cobellis G., Missero C., Di Lauro R. Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation. Oncogene 1998, 17:2047-2057.
30. Coclet J., Lamy F., Rickaert F., Dumont J.E., Roger P.P. Intermediate filaments in normal thyrocytes: modulation of vimentin expression in primary cultures. Mol. Cell Endocrinol. 1991, 76:135-148.
31. Contor L., Lamy F., Lecocq R., Roger P.P., Dumont J.E. Differential protein phosphorylation in induction of thyroid cell proliferation by thyrotropin, epidermal growth factor, or phorbol ester. Mol. Cell Biol. 1988, 8:2494-2503.
32. Coppee F., Gerard A.C., Denef J.F., Ledent C., Vassart G., Dumont J.E., Parmentier M. Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene. Oncogene 1996, 13:1471-1482.
33. Coulonval K., Vandeput F., Stein R., Kozma S., Lamy F., Dumont J.E. Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochem. J. 2000, 348:351-358.
34. Coulonval K., Bockstaele L., Paternot S., Dumont J.E., Roger P.P. The cyclin D3-CDK4-p27kip1 holoenzyme in thyroid epithelial cells: activation by TSH, inhibition by TGFbeta, and phosphorylations of its subunits demonstrated by two-dimensional gel electrophoresis. Exp. Cell Res. 2003, 291:135-149.
35. Coulonval K., Maenhaut C., Dumont J.E., Lamy F. Phosphorylation of the three Rb protein family members is a common step of the cAMP-, the growth factor, and the phorbol ester-mitogenic cascades but is not necessary for the hypertrophy induced by insulin. Exp. Cell Res. 1997, 233:395-398.
36. Couto J.P., Prazeres H., Castro P., Lima J., Maximo V., Soares P., Sobrinho-Simoes M. How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer. J. Clin. Pathol. 2009, 62:414-421.
37. Croyle M., Akeno N., Knauf J.A., Fabbro D., Chen X., Baumgartner J.E., Lane H.A., Fagin J.A. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 2008, 68:4183-4191.
38. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
39. De Falco V., Castellone M.D., De Vita G., Cirafici A.M., Hershman J.M., Guerrero C., Fusco A., Melillo R.M., Santoro M. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res. 2007, 67:381-390.
40. De Vita G., Bauer L., da Costa V.M., De Felice M., Baratta M.G., De Menna M., Di Lauro R. Dose-dependent inhibition of thyroid differentiation by RAS oncogenes. Mol. Endocrinol. 2005, 19:76-89.
41. De Vita G., Berlingieri M.T., Visconti R., Castellone M.D., Viglietto G., Baldassarre G., Zannini M., Bellacosa A., Tsichlis P.N., Fusco A., Santoro M. Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Res. 2000, 60:3916-3920.
42. Deleu S., Pirson I., Clermont F., Nakamura T., Dumont J.E., Maenhaut C. Immediate early gene expression in dog thyrocytes in response to growth, proliferation and differentiation stimuli. J. Cell. Physiol. 1999, 181:342-354.
43. Deleu S., Pirson I., Coulonval K., Drouin A., Taton M., Clermont F., Roger P., Nakamura T., Dumont J.E., Maenhaut C. IGF-1 or insulin, and the TSH cyclic AMP cascade separately control dog and human thyroid cell growth and DNA synthesis and complement each other in inducing mitogenesis. Mol. Cell. Endocrinol. 1999, 149:41-51.
44. Delys L., Detours V., Franc B., Thomas G., Bogdanova T., Tronko M., Libert F., Dumont J.E., Maenhaut C. Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 2007, 26:7894-7903.
45. Depoortere F., Dumont J.E., Roger P.P. Paradoxical accumulation of the cyclin-dependent kinase inhibitor p27kip1 during the cAMP-dependent mitogenic stimulation of thyroid epithelial cells. J. Cell Sci. 1996, 109:1759-1764.
46. Depoortere F., Pirson I., Bartek J., Dumont J.E., Roger P.P. Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1). Mol. Biol. Cell 2000, 11:1061-1076.
47. Depoortere F., Van Keymeulen A., Lukas J., Costagliola S., Bartkova J., Dumont J.E., Bartek J., Roger P.P., Dremier S. A requirement for cyclin D3-cyclin-dependent kinase (cdk)-4 assembly in the cyclic adenosine monophosphate-dependent proliferation of thyrocytes. J. Cell Biol. 1998, 140:1427-1439.
48. Di Cristofaro J., Marcy M., Vasko V., Sebag F., Fakhry N., Wynford-Thomas D., De Micco C. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum. Pathol. 2006, 37:824-830.
49. Di Renzo M.F., Olivero M., Ferro S., Prat M., Bongarzone I., Pilotti S., Belfiore A., Costantino A., Vigneri R., Pierotti M.A. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 1992, 7:2549-2553.
50. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., Fulton L., Fulton R.S., Zhang Q., Wendl M.C., Lawrence M.S., Larson D.E., Chen K., Dooling D.J., Sabo A., Hawes A.C., Shen H., Jhangiani S.N., Lewis L.R., Hall O., Zhu Y., Mathew T., Ren Y., Yao J., Scherer S.E., Clerc K., Metcalf G.A., Ng B., Milosavljevic A., Gonzalez-Garay M.L., Osborne J.R., Meyer R., Shi X., Tang Y., Koboldt D.C., Lin L., Abbott R., Miner T.L., Pohl C., Fewell G., Haipek C., Schmidt H., Dunford-Shore B.H., Kraja A., Crosby S.D., Sawyer C.S., Vickery T., Sander S., Robinson J., Winckler W., Baldwin J., Chirieac L.R., Dutt A., Fennell T., Hanna M., Johnson B.E., Onofrio R.C., Thomas R.K., Tonon G., Weir B.A., Zhao X., Ziaugra L., Zody M.C., Giordano T., Orringer M.B., Roth J.A., Spitz M.R., Wistuba I.I., Ozenberger B., Good P.J., Chang A.C., Beer D.G., Watson M.A., Ladanyi M., Broderick S., Yoshizawa A., Travis W.D., Pao W., Province M.A., Weinstock G.M., Varmus H.E., Gabriel S.B., Lander E.S., Gibbs R.A., Meyerson M., Wilson R.K. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
51. Dremier S., Milenkovic M., Blancquaert S., Dumont J.E., Doskeland S.O., Maenhaut C., Roger P.P. Cyclic adenosine 3′,5′-monophosphate (cAMP)-dependent protein kinases, but not exchange proteins directly activated by cAMP (Epac), mediate thyrotropin/cAMP-dependent regulation of thyroid cells. Endocrinology 2007, 148:4612-4622.
52. Dremier S., Pohl V., Poteet-Smith C., Roger P.P., Corbin J., Doskeland S.O., Dumont J.E., Maenhaut C. Activation of cyclic AMP-dependent kinase is required but may not be sufficient to mimic cyclic AMP-dependent DNA synthesis and thyroglobulin expression in dog thyroid cells. Mol. Cell. Biol. 1997, 17:6717-6726.
53. Dremier S., Taton M., Coulonval K., Nakamura T., Matsumoto K., Dumont J.E. Mitogenic, dedifferentiating, and scattering effects of hepatocyte growth factor on dog thyroid cells. Endocrinology 1994, 135:135-140.
54. Dumont J.E., Dremier S., Pirson I., Maenhaut C. Cross signaling, cell specificity, and physiology. Am. J. Physiol. Cell Physiol. 2002, 283:C2-28.
55. Dumont J.E., Jauniaux J.C., Roger P.P. The cyclic AMP-mediated stimulation of cell proliferation. Trends. Biochem. Sci. 1989, 14:67-71.
56. Dumont J.E., Lamy F., Roger P., Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol. Rev. 1992, 72:667-697.
57. Dumont J.E., Pecasse F., Maenhaut C. Crosstalk and specificity in signalling. Are we crosstalking ourselves into general confusion? Cell Signal. 2001, 13:457-463.
58. Errick J.E., Ing K.W., Eggo M.C., Burrow G.N. Growth and differentiation in cultured human thyroid cells: effects of epidermal growth factor and thyrotropin. in vitro Cell Dev. Biol. 1986, 22:28-36.
59. Fuhrer D., Wonerow P., Willgerodt H., Paschke R. Identification of a new thyrotropin receptor germline mutation (Leu629Phe) in a family with neonatal onset of autosomal dominant nonautoimmune hyperthyroidism. J. Clin. Endocrinol. Metab. 1997, 82:4234-4238.
60. Fusco A., Berlingieri M.T., Di-Fiore P.P., Portella G., Grieco M., Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell Biol. 1987, 7:3365-3370.
61. Garcia-Rostan G., Costa A.M., Pereira-Castro I., Salvatore G., Hernandez R., Hermsem M.J., Herrero A., Fusco A., Cameselle-Teijeiro J., Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005, 65:10199-10207.
62. Garcia-Rostan G., Tallini G., Herrero A., D'Aquila T.G., Carcangiu M.L., Rimm D.L. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999, 59:1811-1815.
63. Gire V., Marshall C.J., Wynford-Thomas D. Activation of mitogen-activated protein kinase is necessary but not sufficient for proliferation of human thyroid epithelial cells induced by mutant Ras. Oncogene 1999, 18:4819-4832.
64. Gire V., Wynford-Thomas D. RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 2000, 19:737-744.
65. Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., Bongarzone I., Pierotti M.A., Della P.G., Fusco A., Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563.
66. Hebrant A., Van Sande J., Roger P.P., Patey M., Klein M., Bournaud C., Savagner F., Leclere J., Dumont J.E., van Staveren W.C., Maenhaut C. Thyroid gene expression in familial nonautoimmune hyperthyroidism shows common characteristics with hyperfunctioning autonomous adenomas. J Clin. Endocrinol. Metab. 2009, 94:2602-2609.
67. Hebrant A., van Staveren W.C., Delys L., Solis D.W., Bogdanova T., Andry G., Roger P., Dumont J.E., Libert F., Maenhaut C. Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp. Cell Res. 2007, 313:3276-3284.
68. Heinrich R., Kraiem Z. The protein kinase A pathway inhibits c-jun and c-fos protooncogene expression induced by the protein kinase C and tyrosine kinase pathways in cultured human thyroid follicles. J. Clin. Endocrinol. Metab. 1997, 82:1839-1844.
69. Hochbaum D., Hong K., Barila G., Ribeiro-Neto F., Altschuler D.L. Epac, in synergy with cAMP-dependent protein kinase (PKA), is required for cAMP-mediated mitogenesis. J Biol. Chem. 2008, 283:4464-4468.
70. Hong K., Lou L., Gupta S., Ribeiro-Neto F., Altschuler D.L. A novel Epac-Rap-PP2A signaling module controls cAMP-dependent Akt regulation. J. Biol. Chem. 2008, 283:23129-23138.
71. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., Wang Y., Trink A., El Naggar A.K., Tallini G., Vasko V., Xing M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 2007, 13:1161-1170.
72. Hou P., Liu D., Xing M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007, 6:377-379.
73. Iavarone C., Acunzo M., Carlomagno F., Catania A., Melillo R.M., Carlomagno S.M., Santoro M., Chiariello M. Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene. J. Biol. Chem. 2006, 281:10567-10576.
74. Isozaki O., Emoto N., Tsushima T., Sato Y., Shizume K., Demura H., Akamizu T., Kohn L.D. Opposite regulation of deoxyribonucleic acid synthesis and iodide uptake in rat thyroid cells by basic fibroblast growth factor: correlation with opposite regulation of c-fos and thyrotropin receptor gene expression. Endocrinology 1992, 131:2723-2732.
75. Jhiang S.M., Sagartz J.E., Tong Q., Parker-Thornburg J., Capen C.C., Cho J.Y., Xing S., Ledent C. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996, 137:375-378.
76. Jin L., Burniat A., Dumont J.E., Miot F., Corvilain B., Franc B. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice. Br. J. Cancer 2008, 99:1874-1883.
77. Jones C.J., Kipling D., Morris M., Hepburn P., Skinner J., Bounacer A., Wyllie F.S., Ivan M., Bartek J., Wynford-Thomas D., Bond J.A. Evidence for a telomere-independent " clock" limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol. Cell Biol. 2000, 20:5690-5699.
78. Kero J., Ahmed K., Wettschureck N., Tunaru S., Wintermantel T., Greiner E., Schutz G., Offermanns S. Thyrocyte-specific Gq/G11 deficiency impairs thyroid function and prevents goiter development. J. Clin. Invest. 2007, 117:2399-2407.
79. Kimura T., Dumont J.E., Fusco A., Golstein J. Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. Eur. J. Endocrinol. 1999, 140:94-103.
80. Kimura T., Van Keymeulen A., Golstein J., Fusco A., Dumont J.E., Roger P.P. Regulation of thyroid cell proliferation by thyrotropin and other factors: a critical evaluation of in vitro models. Endocr. Rev. 2001, 22:631-656.
81. Kirschner L.S., Kusewitt D.F., Matyakhina L., Towns W.H., Carney J.A., Westphal H., Stratakis C.A. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res. 2005, 65:4506-4514.
82. Knauf J.A., Ma X., Smith E.P., Zhang L., Mitsutake N., Liao X.H., Refetoff S., Nikiforov Y.E., Fagin J.A. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005, 65:4238-4245.
83. Knostman K.A., Venkateswaran A., Zimmerman B., Capen C.C., Jhiang S.M. Creation and characterization of a doxycycline-inducible mouse model of thyroid-targeted RET/PTC1 oncogene and luciferase reporter gene coexpression. Thyroid 2007, 17:1181-1188.
84. Kopp P., Van Sande J., Parma J., Duprez L., Gerber H., Joss E., Jameson J.L., Dumont J.E., Vassart G. Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N. Engl. J. Med. 1995, 332:150-154.
85. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., Fletcher J.A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000, 289:1357-1360.
86. Kupperman E., Wen W., Meinkoth J.L. Inhibition of thyrotropin-stimulated DNA synthesis by microinjection of inhibitors of cellular Ras and cyclic AMP-dependent protein kinase. Mol. Cell Biol. 1993, 13:4477-4484.
87. Kupperman E., Wofford D., Wen W., Meinkoth J.L. Ras inhibits thyroglobulin expression but not cyclic adenosine monophosphate-mediated signaling in Wistar rat thyrocytes. Endocrinology 1996, 137:96-104.
88. Lamy F., Roger P., Lecocq R., Dumont J.E. Protein synthesis during induction of DNA replication in thyroid epithelial cells: evidence for late markers of distinct mitogenic pathways. J. Cell Physiol. 1989, 138:568-578.
89. Lamy F., Wilkin F., Baptist M., Posada J., Roger P.P., Dumont J.E. Phosphorylation of mitogen-activated protein kinases is involved in the epidermal growth factor and phorbol ester, but not in the thyrotropin/cAMP, thyroid mitogenic pathway. J. Biol. Chem. 1993, 268:8398-8401.
90. Lania A., Mantovani G., Spada A. G protein mutations in endocrine diseases. Eur. J. Endocrinol. 2001, 145:543-559.
91. Ledent C., Dumont J.E., Vassart G., Parmentier M. Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J. 1992, 11:537-542.
92. Ledent C., Parmentier M., Maenhaut C., Taton M., Pirson I., Lamy F., Roger P., Dumont J.E. The TSH cyclic AMP cascade in the control of thyroid cell proliferation: the story of a concept. Thyroidology 1991, 3:97-101.
93. Lewis A.E., Fikaris A.J., Prendergast G.V., Meinkoth J.L. Thyrotropin and serum regulate thyroid cell proliferation through differential effects on p27 expression and localization. Mol. Endocrinol. 2004, 18:2321-2332.
94. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16:64-67.
95. Logan A., Black E.G., Gonzalez A.M., Buscaglia M., Sheppard M.C. Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells?. Endocrinology 1992, 130:2363-2372.
96. Lou L., Urbani J., Ribeiro-Neto F., Altschuler D.L. cAMP inhibition of Akt is mediated by activated and phosphorylated Rap1b. J Biol. Chem. 2002, 277:32799-32806.
97. Lukas J., Bartkova J., Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell. Biol. 1996, 16:6917-6925.
98. Lyons J., Landis C.A., Harsh G., Vallar L., Grunewald K., Feichtinger H., Duh Q.Y., Clark O.H., Kawasaki E., Bourne H.R. Two G protein oncogenes in human endocrine tumors. Science 1990, 249:655-659.
99. Lyons R.M., Moses H.L. Transforming growth factors and the regulation of cell proliferation. Eur. J. Biochem. 1990, 187:467-473.
100. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10:307-318.
101. Maenhaut C., Van Sande J., Libert F., Abramowicz M., Parmentier M., Vanderhaegen J.J., Dumont J.E., Vassart G., Schiffmann S. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem. Biophys. Res. Commun. 1990, 173:1169-1178.
102. Marques A.R., Espadinha C., Catarino A.L., Moniz S., Pereira T., Sobrinho L.G., Leite V. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 2002, 87:3947-3952.
103. Medina D.L., Velasco J.A., Santisteban P. Somatostatin is expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated down-regulation of the cyclin-dependent kinase inhibitor p27kip1. Endocrinology 1999, 140:87-95.
104. Meinkoth J.L., Goldsmith P.K., Spiegel A.M., Feramisco J.R., Burrow G.N. Inhibition of thyrotropin-induced DNA synthesis in thyroid follicular cells by microinjection of an antibody to the stimulatory G protein of adenylate cyclase. Gs. J. Biol. Chem. 1992, 267:13239-13245.
105. Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 2007, 17:707-715.
106. Mesa C., Mirza M., Mitsutake N., Sartor M., Medvedovic M., Tomlinson C., Knauf J.A., Weber G.F., Fagin J.A. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 2006, 66:6521-6529.
107. Miccadei S., Provenzano C., Mojzisek M., Giorgio N.P., Civitareale D. Retinoblastoma protein acts as Pax 8 transcriptional coactivator. Oncogene 2005, 24:6993-7001.
108. Michiels F.M., Caillou B., Talbot M., Dessarps-Freichey F., Maunoury M.T., Schlumberger M., Mercken L., Monier R., Feunteun J. Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:10488-10492.
109. Miller K.A., Yeager N., Baker K., Liao X.H., Refetoff S., Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res. 2009, 69:3689-3694.
110. Miller M.J., Prigent S., Kupperman E., Rioux L., Park S.H., Feramisco J.R., White M.A., Rutkowski J.L., Meinkoth J.L. RalGDS functions in Ras- and c-AMP-mediated growth stimulation. J. Biol. Chem. 1997, 272:5600-5605.
111. Minoletti F., Butti M.G., Coronelli S., Miozzo M., Sozzi G., Pilotti S., Tunnacliffe A., Pierotti M.A., Bongarzone I. The two genes generating RET/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes Cancer 1994, 11:51-57.
112. Mitsutake N., Knauf J.A., Mitsutake S., Mesa C., Zhang L., Fagin J.A. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005, 65:2465-2473.
113. Mitsutake N., Miyagishi M., Mitsutake S., Akeno N., Mesa J.C., Knauf J.A., Zhang L., Taira K., Fagin J.A. BRAF mediates RET/PTC-induced MAPK activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 2006, 147:1014-1019.
114. Miyagi E., Braga-Basaria M., Hardy E., Vasko V., Burman K.D., Jhiang S., Saji M., Ringel M.D. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol. Carcinog. 2004, 41:98-107.
115. Motti M.L., Boccia A., Belletti B., Bruni P., Troncone G., Cito L., Monaco M., Chiappetta G., Baldassarre G., Palombini L., Fusco A., Viglietto G. Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland. Oncogene 2003, 22:7576-7586.
116. Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., Ohtsuru A., Saenko V.A., Kanematsu T., Yamashita S. Clinical implication of hot spot BRAF mutation V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 2003, 88:4393-4397.
117. Nguyen L.Q., Kopp P., Martinson F., Stanfield K., Roth S.I., Jameson J.L. A dominant negative CREB (cAMP response element-binding protein) isoform inhibits thyrocyte growth, thyroid-specific gene expression, differentiation, and function. Mol. Endocrinol. 2000, 14:1448-1461.
118. Nikiforov Y.E. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr. Pathol. 2004, 15:319-327.
119. Nikiforov Y.E., Rowland J.M., Bove K.E., Monforte-Munoz H., Fagin J.A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997, 57:1690-1694.
120. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., Santoro M., Fagin J.A., Nikiforov Y.E. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003, 88:5399-5404.
121. Parma J., Duprez L., Van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993, 365:649-651.
122. Paternot S., Arsenijevic T., Coulonval K., Bockstaele L., Dumont J.E., Roger P.P. Distinct specificities of pRb phosphorylation by CDK4 activated by Cyclin D1 or Cyclin D3: differential involvement in the distinct mitogenic modes of thyroid epithelial cells. Cell Cycle 2006, 5:61-70.
123. Paternot, S., Bockstaele, L., Bisteau, X., Kooken, H., Coulonval, K., Roger, P.P., 2010. Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle 9, in press.
124. Paternot S., Coulonval K., Dumont J.E., Roger P.P. Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells. J. Biol. Chem. 2003, 278:26533-26540.
125. Paternot S., Dumont J.E., Roger P.P. Differential utilization of cyclin D1 and cyclin D3 in the distinct mitogenic stimulations of human thyrocytes by growth factors and TSH. Mol. Endocrinol. 2006, 20:3279-3292.
126. Pirson I., Coulonval K., Lamy F., Dumont J.E. c-Myc expression is controlled by the mitogenic cAMP-cascade in thyrocytes. J. Cell Physiol. 1996, 168:59-70.
127. Pohl V., Abramowicz M., Vassart G., Dumont J.E., Roger P.P. Thyroperoxidase mRNA in quiescent and proliferating thyroid epithelial cells: expression and subcellular localization studied by in situ hybridization. Eur. J. Cell Biol. 1993, 62:94-104.
128. Pohl V., Roger P.P., Christophe D., Pattyn G., Vassart G., Dumont J.E. Differentiation expression during proliferative activity induced through different pathways: in situ hybridization study of thyroglobulin gene expression in thyroid epithelial cells. J. Cell Biol. 1990, 111:663-672.
129. Polak M., Legac I., Vuillard E., Guibourdenche J., Castanet M., Luton D. Congenital hyperthyroidism: the fetus as a patient. Horm. Res. 2006, 65:235-242.
130. Powell D.J., Russell J., Nibu K., Li G., Rhee E., Liao M., Goldstein M., Keane W.M., Santoro M., Fusco A., Rothstein J.L. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998, 58:5523-5528.
131. Powell N., Jeremiah S., Morishita M., Dudley E., Bethel J., Bogdanova T., Tronko M., Thomas G. Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J. Pathol. 2005, 205:558-564.
132. Rao A.S., Kremenevskaja N., Resch J., Brabant G. Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling. Eur. J Endocrinol. 2005, 153:929-938.
133. Raspe E., Laurent E., Andry G., Dumont J.E. ATP, bradykinin, TRH and TSH activate the Ca(2+)-phosphatidylinositol cascade of human thyrocytes in primary culture. Mol. Cell Endocrinol. 1991, 81:175-183.
134. Raspe E., Roger P.P., Dumont J.E. Carbamylcholine, TRH. PGF2 alpha and fluoride enhance free intracellular Ca++ and Ca++ translocation in dog thyroid cells. Biochem. Biophys. Res. Commun. 1986, 141:569-577.
135. Reuse S., Maenhaut C., Dumont J.E. Regulation of protooncogenes c-fos and c-myc expressions by protein tyrosine kinase, protein kinase C, and cyclic AMP mitogenic pathways in dog primary thyrocytes: a positive and negative control by cyclic AMP on c-myc expression. Exp. Cell Res. 1990, 189:33-40.
136. Reuse S., Pirson I., Dumont J.E. Differential regulation of protooncogenes c-jun and jun D expressions by protein tyrosine kinase, protein kinase C, and cyclic-AMP mitogenic pathways in dog primary thyrocytes: TSH and cyclic-AMP induce proliferation but downregulate C-jun expression. Exp. Cell Res. 1991, 196:210-215.
137. Rhoden K.J., Unger K., Salvatore G., Yilmaz Y., Vovk V., Chiappetta G., Qumsiyeh M.B., Rothstein J.L., Fusco A., Santoro M., Zitzelsberger H., Tallini G. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab. 2006, 91:2414-2423.
138. Ribeiro-Neto F., Urbani J., Lemee N., Lou L., Altschuler D.L. On the mitogenic properties of Rap1b: cAMP-induced G(1)/S entry requires activated and phosphorylated Rap1b. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:5418-5423.
139. Ringel M.D. " Thyroid cancer" cell line misidentification: a time for proactive change. J Clin. Endocrinol. Metab. 2008, 93:4226-4227.
140. Rivas M., Santisteban P. TSH-activated signaling pathways in thyroid tumorigenesis. Mol. Cell Endocrinol. 2003, 213:31-45.
141. Rocha A.S., Paternot S., Coulonval K., Dumont J.E., Soares P., Roger P.P. Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol. Biol. Cell 2008, 19:4814-4825.
142. Rochefort P., Caillou B., Michiels F.M., Ledent C., Talbot M., Schlumberger M., Lavelle F., Monier R., Feunteun J. Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter. Oncogene 1996, 12:111-118.
143. Roger P., Taton M., Van Sande J., Dumont J.E. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J. Clin. Endocrinol. Metab. 1988, 66:1158-1165.
144. Roger P.P., Baptist M., Dumont J.E. A mechanism generating heterogeneity in thyroid epithelial cells: suppression of the thyrotropin/cAMP-dependent mitogenic pathway after cell division induced by cAMP-independent factors. J. Cell Biol. 1992, 117:383-393.
145. Roger P.P., Demartin S., Dumont J.E. Nature of the critical labile event that controls RB phosphorylation in the cyclic AMP-dependent cell cycle of thyrocytes in primary culture. Exp. Cell Res. 1999, 252:492-498.
146. Roger P.P., Dumont J.E. Epidermal growth factor controls the proliferation and the expression of differentiation in canine thyroid cells in primary culture. FEBS Lett. 1982, 144:209-212.
147. Roger P.P., Dumont J.E. Factors controlling proliferation and differentiation of canine thyroid cells cultured in reduced serum conditions: effects of thyrotropin, cyclic AMP and growth factors. Mol. Cell Endocrinol. 1984, 36:79-93.
148. Roger P.P., Reuse S., Maenhaut C., Dumont J.E. Multiple facets of the modulation of growth by cAMP. Vitam. Horm. 1995, 51:59-191.
149. Roger P.P., Reuse S., Servais P., Van Heuverswyn B., Dumont J.E. Stimulation of cell proliferation and inhibition of differentiation expression by tumor-promoting phorbol esters in dog thyroid cells in primary culture. Cancer Res. 1986, 46:898-906.
150. Roger P.P., Rickaert F., Huez G., Authelet M., Hofmann F., Dumont J.E. Microinjection of catalytic subunit of cyclic AMP-dependent protein kinase triggers acute morphological changes in thyroid epithelial cells. FEBS Lett. 1988, 232:409-413.
151. Roger P.P., Servais P., Dumont J.E. Stimulation by thyrotropin and cyclic AMP of the proliferation of quiescent canine thyroid cells cultured in a defined medium containing insulin. FEBS Lett. 1983, 157:323-329.
152. Roger P.P., Servais P., Dumont J.E. Induction of DNA synthesis in dog thyrocytes in primary culture: synergistic effects of thyrotropin and cyclic AMP with epidermal growth factor and insulin. J. Cell Physiol. 1987, 130:58-67.
153. Roger P.P., Van Heuverswyn B., Lambert C., Reuse S., Vassart G., Dumont J.E. Antagonistic effects of thyrotropin and epidermal growth factor on thyroglobulin mRNA level in cultured thyroid cells. Eur. J. Biochem. 1985, 152:239-245.
154. Romeo H.E., Diaz M.C., Ceppi J., Zaninovich A.A., Cardinali D.P. Effect of inferior laryngeal nerve section on thyroid function in rats. Endocrinology 1988, 122:2527-2532.
155. Russo D., Arturi F., Schlumberger M., Caillou B., Monier R., Filetti S., Suarez H.G. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene 1995, 11:1907-1911.
156. Saavedra H.I., Knauf J.A., Shirokawa J.M., Wang J., Ouyang B., Elisei R., Stambrook P.J., Fagin J.A. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000, 19:3948-3954.
157. Santelli G., de F.V., Chiappetta G., D'Alessio A., Califano D., Mineo A., Monaco C., Vecchio G. Thyroid specific expression of the Ki-ras oncogene in transgenic mice. Adv. Exp. Med. Biol. 1993, 348:59-62.
158. Santoro M., Chiappetta G., Cerrato A., Salvatore D., Zhang L., Manzo G., Picone A., Portella G., Santelli G., Vecchio G., Fusco A. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996, 12:1821-1826.
159. Santoro M., Dathan N.A., Berlingieri M.T., Bongarzone I., Paulin C., Grieco M., Pierotti M.A., Vecchio G., Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994, 9:509-516.
160. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., Di Nicolantonio F., Saletti P., De Dosso S., Mazzucchelli L., Frattini M., Siena S., Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009, 69:1851-1857.
161. Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 2008, 93:4331-4341.
162. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
163. The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
164. Thomas R. Logical analysis of systems comprising feedback loops. J. Theor. Biol. 1978, 73:631-656.
165. Tominaga T., Dela Cruz J., Burrow G.N., Meinkoth J.L. Divergent patterns of immediate early gene expression in response to thyroid-stimulating hormone and insulin-like growth factor I in Wistar rat thyrocytes. Endocrinology 1994, 135:1212-1219.
166. Tonacchera M., Vitti P., Agretti P., Ceccarini G., Perri A., Cavaliere R., Mazzi B., Naccarato A.G., Viacava P., Miccoli P., Pinchera A., Chiovato L. Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms. J. Clin. Endocrinol. Metab. 1999, 84:4155-4158.
167. Trovato M., Villari D., Bartolone L., Spinella S., Simone A., Violi M.A., Trimarchi F., Batolo D., Benvenga S. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 1998, 8:125-131.
168. Trovisco V., Vieira d.C.I., Soares P., Maximo V., Silva P., Magalhaes J., Abrosimov A., Guiu X.M., Sobrinho-Simoes M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 2004, 202:247-251.
169. Tsygankova O.M., Kupperman E., Wen W., Meinkoth J.L. Cyclic AMP activates Ras. Oncogene 2000, 19:3609-3615.
170. Tsygankova O.M., Saavedra A., Rebhun J.F., Quilliam L.A., Meinkoth J.L. Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A. Mol. Cell Biol. 2001, 21:1921-1929.
171. Unger K., Malisch E., Thomas G., Braselmann H., Walch A., Jackl G., Lewis P., Lengfelder E., Bogdanova T., Wienberg J., Zitzelsberger H. Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC. Oncogene 2008, 27:4592-4602.
172. Unger K., Zitzelsberger H., Salvatore G., Santoro M., Bogdanova T., Braselmann H., Kastner P., Zurnadzhy L., Tronko N., Hutzler P., Thomas G. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 2004, 89:4272-4279.
173. Uyttersprot N., Costagliola S., Dumont J.E., Miot F. Requirement for cAMP-response element (CRE) binding protein/CRE modulator transcription factors in thyrotropin-induced proliferation of dog thyroid cells in primary culture. Eur. J. Biochem. 1999, 259:370-378.
174. Van Keymeulen A., Bartek J., Dumont J.E., Roger P.P. Cyclin D3 accumulation and activity integrate and rank the comitogenic pathways of thyrotropin and insulin in thyrocytes in primary culture. Oncogene 1999, 18:7351-7359.
175. Van Keymeulen A., Deleu S., Bartek J., Dumont J.E., Roger P.P. Respective roles of carbamylcholine and cyclic AMP in their synergistic regulation of cell cycle in thyroid primary cultures. Endocrinology 2001, 142:1251-1259.
176. Van Keymeulen A., Dumont J.E., Roger P.P. TSH induces insulin receptors that mediate insulin co-stimulation of growth in normal human thyroid cells. Biochem. Biophys. Res. Commun. 2000, 279:202-207.
177. Van Keymeulen A., Roger P.P., Dumont J.E., Dremier S. TSH and cAMP do not signal mitogenesis through Ras activation. Biochem. Biophys. Res. Commun. 2000, 273:154-158.
178. Van Sande J., Dequanter D., Lothaire P., Massart C., Dumont J.E., Erneux C. Thyrotropin stimulates the generation of inositol 1,4,5-trisphosphate in human thyroid cells. J Clin. Endocrinol. Metab 2006, 91:1099-1107.
179. Van Sande J., Lefort A., Beebe S., Roger P., Perret J., Corbin J., Dumont J.E. Pairs of cyclic AMP analogs, that are specifically synergistic for type I and type II cAMP-dependent protein kinases, mimic thyrotropin effects on the function, differentiation expression and mitogenesis of dog thyroid cells. Eur. J. Biochem. 1989, 183:699-708.
180. Van Sande J., Parma J., Tonacchera M., Swillens S., Dumont J., Vassart G. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J. Clin. Endocrinol. Metab. 1995, 80:2577-2585.
181. van Staveren W.C., Solis D.W., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C. Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res. 2007, 67:8113-8120.
182. van Staveren W.C., Solis D.Y., Hebrant A., Detours V., Dumont J.E., Maenhaut C. Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells? Biochim. Biophys. Acta 2009, 1795:92-103.
183. van Staveren W.C.G., Weiss Solis D., Delys L., Venet D., Cappello M., Andry G., Dumont J.E., Libert F., Detours V., Maenhaut C. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:413-418.
184. Vandeput F., Perpete S., Coulonval K., Lamy F., Dumont J.E. Role of the different mitogen-activated protein kinase subfamilies in the stimulation of dog and human thyroid epithelial cell proliferation by cyclic adenosine 5′-monophosphate and growth factors. Endocrinology 2003, 144:1341-1349.
185. Vanvooren V., Uchino S., Duprez L., Costa M.J., Vandekerckhove J., Parma J., Vassart G., Dumont J.E., Van Sande J., Noguchi S. Oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in the Japanese population. Eur. J. Endocrinol. 2002, 147:287-291.
186. Vella V., Pandini G., Sciacca L., Mineo R., Vigneri R., Pezzino V., Belfiore A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab. 2002, 87:245-254.
187. Vitagliano D., Carlomagno F., Motti M.L., Viglietto G., Nikiforov Y.E., Nikiforova M.N., Hershman J.M., Ryan A.J., Fusco A., Melillo R.M., Santoro M. Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res. 2004, 64:3823-3829.
188. Vogt P.K., Kang S., Elsliger M.A., Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 2007, 32:342-349.
189. Vuchak L.A., Tsygankova O.M., Prendergast G.V., Meinkoth J.L. Protein kinase A and B-Raf mediate extracellular signal-regulated kinase activation by thyrotropin. Mol. Pharmacol. 2009, 76:1123-1129.
190. Wang J., Knauf J.A., Basu S., Puxeddu E., Kuroda H., Santoro M., Fusco A., Fagin J.A. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol. Endocrinol. 2003, 17:1425-1436.
191. Wang Y., Hou P., Yu H., Wang W., Ji M., Zhao S., Yan S., Sun X., Liu D., Shi B., Zhu G., Condouris S., Xing M. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J. Clin. Endocrinol. Metab 2007, 92:2387-2390.
192. Williams D.W., Williams E.D., Wynford-Thomas D. Loss of dependence on IGF-1 for proliferation of human thyroid adenoma cells. Br. J. Cancer 1988, 57:535-539.
193. Williams D.W., Williams E.D., Wynford-Thomas D. Evidence for autocrine production of IGF-1 in human thyroid adenomas. Mol. Cell Endocrinol. 1989, 61:139-143.
194. Williams E.D., Abrosimov A., Bogdanova T., Demidchik E.P., Ito M., LiVolsi V., Lushnikov E., Rosai J., Sidorov Y., Tronko M.D., Tsyb A.F., Vowler S.L., Thomas G.A. Thyroid carcinoma after Chernobyl latent period, morphology and aggressiveness. Br. J. Cancer 2004, 90:2219-2224.
195. Xing M., Clark D., Guan H., Ji M., Dackiw A., Carson K.A., Kim M., Tufaro A., Ladenson P., Zeiger M., Tufano R. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol. 2009, 27:2977-2982.
196. Yeager N., Klein-Szanto A., Kimura S., Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res. 2007, 67:959-966.
197. Zeiger M.A., Saji M., Gusev Y., Westra W.H., Takiyama Y., Dooley W.C., Kohn L.D., Levine M.A. Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice. Endocrinology 1997, 138:3133-3140.
198. Zeng Q., Chen G.G., Vlantis A.C., van Hasselt C.A. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif. 2007, 40:921-935.
199. Zhu Z., Ciampi R., Nikiforova M.N., Gandhi M., Nikiforov Y.E. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 2006, 91:3603-3610.